INVO Fertility Inc(IVF) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 0 | EPS (ttm) | 511.8 | Insider Own | 1.5% | Shs Outstand | 1.2M | Perf Week | -19.74% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 98.56% | Insider Trans | - | Shs Float | 1.2M | Perf Month | -46.49% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -20.8 | Inst Own | 98.5% | Short Float | 0.56% | Perf Quarter | -56.43% |
| Income | -0.01B | P/S | 0.29 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.01 | Perf Half Y | -75.79% |
| Sales | 0.01B | P/B | 0.07 | EPS next 5Y | - | ROA | -30.8% | Short Interest | 0.01M | Perf YTD | -87.84% |
| Book/sh | 28.05 | P/C | 0.59 | EPS past 3/5Y | 86.33% - | ROE | -161.6% | 52W High | -98.28% ($106.32) | Perf Year | -97.88% |
| Cash/sh | 3.12 | P/FCF | - | Sales past 3/5Y | 102.64% - | ROIC | -69.2% | 52W Low | 15.09% ($1.59) | Perf 3Y | -99.98% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 99.18% | Gross Margin | 35.3% | Volatility(W/M) | 19.64% 13.71% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | 0.37 | Sales Y/Y TTM | 13.76% | Oper. Margin | -78.7% | ATR (14) | 0.31 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 0.6 | EPS Q/Q | - | Profit Margin | -92.3% | RSI (14) | 24.83 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.7 | Sales Q/Q | 15.8% | SMA20 | -24.82% ($2.43) | Beta | 2.42 | Target Price | $80 |
| Payout | - | Debt/Eq | 0.24 | Earnings | 2026/8/17 | SMA50 | -44.46% ($3.29) | Rel Volume | 0.1 | Prev Close | $1.91 |
| Employees | 40 | LT Debt/Eq | 0.15 | EPS/Sales Surpr. | - | SMA200 | -79.91% ($9.11) | Avg Volume(3M) | 0.53M | Price | $1.83 |
| IPO | 2008/11/11 | Option/Short | No/Yes | Trades | 717 | Volume | 55,383 | Change | -4.19% |
(INVO Fertility) is a Nasdaq-listed healthcare company in the U.S. focused on infertility treatment. It operates two core business lines: directly running INVO Center clinics, which offer intravaginal culture (IVC) procedures using its proprietary medical device INVOcell, as well as conventional in vitro fertilization (IVF) clinics; and selling and distributing the INVOcell device to third-party clinics.
Over the past 1 year, on the lower side
98% below its 1-year high.
Traded less than usual. That is 10% of its average volume.
IVF has weak earnings and a weak balance sheet
Of every $100 in sales, $78.70 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +98.6% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $29. Peers typically go for $145. Compared with its own 2-year average, it is 100% cheaper now.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Positive and negative signals are mixed
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 98.5%.
Tap to view numbers
It ranks #138 of 140 in the industry
Based on market cap of $2M.
FAQ
What kind of company is IVF?
IVF belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of IVF?
The market cap of IVF is approximately $2M, ranking 5,786 within its sector.
What is the P/E ratio of IVF?
IVF has a P/E ratio of approximately 0.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for IVF?
IVF has recorded a 52-week high of $106.32 and a low of $1.59.
